Payer decision making for next-generation sequencing–based genetic tests: insights from cell-free DNA prenatal screening by Dervan, Andrew P. et al.
Payer Decision-Making for Next Generation Sequencing-Based 
Genetic Tests: Insights from cell-free DNA prenatal genetic 
screening
Andrew P. Dervan, MD, MBA1, Patricia A. Deverka, MD, MS2,3, Julia R. Trosman, PHD, 
MBA4,5,6, Christine B. Weldon, MBA4,5,6, Michael P. Douglas, MS4, and Kathryn A. Phillips, 
PHD4,7,8
1Division of Medical Genetics, Department of Medicine, University of Washington, Seattle
2American Institutes for Research, Chapel Hill
3University of North Carolina, Eshelman School of Pharmacy, Center for Pharmacogenomics and 
Individualized Therapy
4Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized 
Medicine (TRANSPERS), University of California San Francisco, San Francisco
5Center for Business Models in Healthcare, Chicago
6Northwestern University Feinberg School of Medicine, Chicago
7Philip R. Lee Institute for Health Policy, University of California San Francisco, San Francisco
8Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San 
Francisco
Abstract
Purpose—Cell-free DNA (cfDNA) prenatal screening tests have been rapidly adopted into 
clinical practice, in part due to positive insurance coverage. We evaluated the framework payers 
used in making coverage decisions to describe a process that should be informative for other 
sequencing tests.
Methods—We analyzed coverage policies from the 19 largest U.S. private payers with publicly 
available policies through February 2016, building from the UCSF TRANSPERS Payer Coverage 
Policy Registry.
Results—All payers studied cover cfDNA screening for detection of trisomies 21, 18 and 13 in 
high risk, singleton pregnancies, based on robust clinical validity (CV) studies and modeled 
evidence of clinical utility (CU). Payers typically evaluated the evidence for each chromosomal 
abnormality separately, although results are offered as part of a panel. Starting in August 2015, 
8/19 payers also cover cfDNA screening in average risk pregnancies, citing recent CV studies and 
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updated professional guidelines. Most payers attempted, but were unable to independently assess 
analytic validity (AV).
Conclusion—Payers utilized the standard evidentiary framework (AV/CV/CU) when evaluating 
cfDNA screening, but varied in their interpretation of the sufficiency of the evidence. Professional 
guidelines, large CV studies and decision analytic models regarding health outcomes appeared 
highly influential in coverage decisions.
Keywords
Non-invasive prenatal testing; next generation sequencing; cell-free DNA; insurance coverage; 
clinical utility
INTRODUCTION
Screening for fetal chromosomal abnormalities in utero has evolved rapidly over the past 
two decades. Trisomy 21 (Down syndrome) is the most common genetic cause of human 
birth defects and provides impetus for the current screening paradigm.1 Traditional 
screening techniques involve ultrasonography and/or maternal serum markers. However, 
even in high risk populations, there are considerable rates of false positive results with 
standard screening, and even some false negative results.2 The idea of capturing placental 
DNA circulating in maternal blood has always held great promise, and since late 2011, 
prenatal genetic screening tests based on circulating cell-free DNA (cfDNA) have been 
offered in the United States. Nevertheless, controversies remain regarding the appropriate 
use of this technology. While cfDNA screening tests are much better at detecting common 
fetal aneuploidies than traditional screening methods, cfDNA screening cannot detect 
structural birth defects nor predict other adverse pregnancy outcomes.3 Conversely, cfDNA 
screening can potentially detect a broader range of genetic conditions than standard 
screening such as sex chromosome imbalances or subchromosomal deletions 
(microdeletions), which have varied newborn, childhood, and adult presentations.
As cfDNA screening tests are not diagnostic, results indicating an increased risk for 
chromosomal imbalance must be confirmed with invasive testing. Patients must be informed 
about this limitation, as well as the potential implications of the breadth of genetic 
information that they may receive. Pre-test counseling by an appropriately knowledgeable 
provider is recommended; however, many screening delivery models lack dedicated genetic 
counselors, leaving increasingly complex counselling to providers who may lack necessary 
time and training, raising concerns about informed patient decision-making.3
Despite these cautionary notes, there has been rapid clinical uptake of cfDNA screening4 
due to both features of the test (e.g., sensitivity, specificity) as well as commercial 
marketing. In the U.S., clinical integration has also been enabled by private insurance 
coverage5, however, how coverage decisions for cfDNA screening tests are made has not 
been systematically examined. Previous reviews of payer decision-making criteria for 
genetic tests broadly revealed that payers use a systematic approach to evaluating underlying 
evidence regarding safety and effectiveness.6,7 Specifically, a test must demonstrate 
adequate evidence of analytic validity, clinical validity and clinical utility in order to be 
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considered “medically necessary” and therefore covered.8 Payer coverage decisions often 
cite publicly available studies and technology assessments to determine whether a new test is 
accurate and reliable (analytic validity), the result is medically meaningful (clinical validity) 
and whether results affect clinical decisions and improve health outcomes (clinical utility).
Experts have questioned whether this evidentiary framework is generalizable to next-
generation sequencing-based tests because of differences in analytical methods and 
technology platforms used for testing, as well as the complexity of the results.9 This issue is 
particularly relevant to cfDNA screening, where the test methodologies are variable, 
competition has fueled extensive marketing to both patients and providers, and the absence 
of published evidence on quality control and quality assurance is a significant concern.10 We 
postulated that careful examination of the evolution of payer coverage decision-making for 
cfDNA screening would be informative for understanding the current process as well as 
potential coverage of future related prenatal tests such as genome-wide microdeletions and 
microduplications, single gene pathogenic variants, and entire fetal genomes. We conducted 
a systematic assessment of coverage policies for cfDNA screening for the 19 largest private 
insurers in the US with publically available policies to examine the evidentiary framework 
for coverage-decision-making, clinical indications for testing, evidence cited, and changes 
over time among the various payers.
MATERIALS AND METHODS
Search Strategy and Policy Selection
To analyze relevant coverage policies, we utilized the University of California – San 
Francisco (UCSF) Center for Translational and Policy Research on Personalized Medicine 
(TRANSPERS) Payer Coverage Registry. This unique registry was developed with a team of 
collaborators from multiple institutions (UCSF, Tufts Medical Center, American Institutes 
for Research, and Center for Business Models in Healthcare) with funding from the National 
Human Genome Research Institute (R01HG007063-S1). The Registry systematically 
synthesizes payer coverage policies to assess which genetic testing panels are covered or not 
covered by payers, what factors relevant to coverage decisions are discussed in policies, and 
how coverage policies vary.
The Registry currently includes coverage policies relevant to whole genome sequencing, 
whole exome sequencing, and multi-gene panels. The Registry includes data on what panels 
and testing indications are reviewed, whether panels are covered or not covered, and the 
evidence and rationales for coverage decisions cited in the policy. The current Registry (Ver.
1) includes policies from the five largest US private payers, based on enrollment. These 
payers represent 128 million enrolled lives.11
For the purposes of this paper, we utilized the Registry and added independent analysis of 
coverage policies of the top 19 payers (as defined by number of lives covered, covering over 
184 million lives) and closely examined policies that pertain to cfDNA screening. We 
identified such additional policies by searching commercial payers’ respective websites 
between November 24, 2015 and February 28, 2016 using the terms “pre-natal,” “non-
invasive,” “fetal,” “aneuploidy,” “cell-free DNA,” “DNA-based,” “sequencing,” “trisomy,” 
Dervan et al. Page 3
Genet Med. Author manuscript; available in PMC 2017 May 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
“Down Syndrome,” “genetic,” and “screening.” Policy titles were screened for applicable 
terms. The most updated policy as of the February 2016 search date was used in our final 
analysis. Of note, fourteen of the policies came from Blue Cross Blue Shield-affiliated 
payers. Each payer’s policy was treated as an independent entity, reflecting their local 
coverage decision-making procedures.
Data Extraction and Coding
For each included policy, two reviewers independently read and extracted relevant data 
elements. Relevant information was coded on 28 items, including dates of revision, positive 
or negative coverage determinations, evidence of analytical and clinical validity and clinical 
utility, references to professional guidelines and health technology assessments, references 
to specific test methodologies, and genetic counseling requirements. Data abstraction was 
limited to the information contained in the coverage policy; original source materials such as 
published studies were not reviewed. The reviewers convened to resolve any discrepancies.
RESULTS
Policy Identification
Fifteen of 19 payers had a coverage policy exclusively focused on cfDNA screening and four 
had policies that addressed the broader topic of prenatal screening. No payer had more than 
one policy that addressed cfDNA screening.
cfDNA screening Coverage by Patient Group and Clinical Condition
In general, coverage policies differentiated between two specific patient subgroups: (1) high 
risk for having a fetus with a common aneuploidy, or (2) average risk (general obstetric 
population) (see Table 1 for definitions). They also describe several types of chromosomal 
abnormalities: Trisomy 21, trisomy 18 (Edwards Syndrome), trisomy 13 (Patau Syndrome), 
sex chromosome aneuploidies, and microdeletions. All 19 policies covered cfDNA screening 
as first line assessment for trisomy 21 in high risk women with singleton pregnancies; and if 
trisomy 21 screening is performed, screening for other common aneuploidies (specifically 
trisomy 18 and trisomy 13) is also covered (Table 2).
However, coverage of cfDNA screening as first line screening for trisomy 21 in average risk 
women with singleton pregnancies varied by payer. Eight of 19 payers cover cfDNA 
screening for trisomy 21 in average risk women. No policies cover routine testing for other 
genetic syndromes, including sex chromosome aneuploidy or microdeletions, with the 
exception of one policy that covers sex chromosome aneuploidy if testing for trisomy 21 is 
being performed (Table 2). All but four policies draw direct attention to the fact that cfDNA 
screening tests are not diagnostic tests, and that no medical decisions should be made with 
the information without a confirmatory diagnostic (invasive) procedure.
Types of Clinical Evidence Cited for Coverage Decisions
Analytical Validity—Ten policies explicitly assessed the evidence base for analytic 
validity (Table 2). The majority of policies reference the conclusions of a 2013 Blue Cross 
Blue Shield Technology Assessment Report that stated that there are no identified studies 
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which provide direct evidence on analytic validity and that they recognize that clinical 
sequencing in general is not standardized or regulated by the FDA. A few payers went 
further and stated conclusions of a 2011 FDA public meeting on massively parallel 
sequencing that suggested that the trend was for analytic validation procedures to be 
application specific and therefore not generalizable across tests. The consistent 
acknowledgement across the ten payer coverage policies was that they lacked access to 
publicly available data and standards to conduct an independent assessment of analytic 
validity, but this reflected the current state of sequencing oversight at the time.
Clinical Validity—In contrast, payers cited numerous studies of clinical validity when 
describing the evidence used to assess cfDNA screening for coverage determinations. An 
illustrative list of some of the most frequently cited evidence sources is provided in Table 3. 
All but one coverage policy summarized or referenced published studies of clinical validity 
for cfDNA screening to detect trisomy 21, trisomy 18 and trisomy 13 in women with high 
risk singleton pregnancies. All of these studies were observational studies. A minority of 
policies (four) did not summarize either clinical validity studies or the overall evidence, but 
they did include clinical validity studies in the policy references.
While 18 policies address clinical validity in high risk singleton pregnancies, only 14 
specifically addressed the clinical validity evidence in average risk pregnancies. All but two 
of those 14 note that the evidence of clinical validity is less robust in this population, 
primarily because there are fewer available studies. Payers differed in their interpretation of 
the sufficiency of these clinical validity data in average risk women, as demonstrated by only 
8/14 payers determining that the data supporting the use of cfDNA screening in average risk 
women were sufficient to consider the tests medically necessary.
For prenatal conditions beyond the three most common chromosomal aneuploidies, such as 
microdeletions and sex chromosome aneuploidy, nine and fourteen policies, respectively, 
cite that data are insufficient for coverage. The one policy that does cover sex chromosome 
aneuploidy does not clarify the evidence used to support that decision.
Clinical Utility—Eleven of 19 policies explicitly reported the evaluation of clinical utility 
as part of their coverage determination. Clinical utility was defined by all policies as a 
change in net health outcomes, with three policies also including a change in “patient 
management” or “clinical decision-making” as part of their definition. In all cases, only 
indirect (modeled) evidence of clinical utility is cited. Published technology assessments, 
which include decision analytic models to demonstrate clinical utility, are common data 
sources, as were several peer-reviewed modeling papers.12–14 These models all defined 
outcomes as correctly identifying trisomies while avoiding unnecessary invasive procedures, 
which carry a risk of miscarriage.
cfDNA screening Coverage by Technology Platform
Three different technology platforms and analysis methodologies underlie the major 
commercially available tests for cfDNA screening. These include massively parallel whole 
genome shotgun sequencing, chromosome-selective massively parallel sequencing paired 
with an array, and single nucleotide analysis only compared against a maternal background 
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reference (Table 4). The results across these 3 different platforms are reported as a risk 
category (e.g. no aneuploidy detected, aneuploidy suspected or aneuploidy detected) 
typically with a residual risk.
No payer policies distinguish coverage based on whether a test uses a specific technology 
platform or a specific data interpretation algorithm. Cited clinical studies were typically 
performed using a single manufacturer’s technology, yet coverage policies cite these single 
manufacturer studies as rationale for covering cfDNA screening generally across technology 
and analysis platforms.
Pre- and Post-test Counseling Requirements
Most policies (12/19) include a general statement recommending pre- and post-test 
counseling, however in no policy is this a pre-authorization requirement. Five of those 12 
policies specifically outline that women should be counseled about the risk of a false 
positive result. The justification for this recommendation is most often professional 
guidelines such as those by the American College of Obstetrics and Gynecology (ACOG), 
which recommends formal genetic counseling for cfDNA screening by an individual with 
experience and expertise in genetic medicine and genetic testing methods (Table 2).
Professional Practice Guidelines
Paralleling the clinical availability of cfDNA screening, numerous professional societies 
have published clinical practice guidelines to encourage appropriate use of these new tests. 
This includes a recent combined committee opinion from ACOG and the Society of 
Maternal Fetal Medicine (SMFM)15, a policy statement from the ACMG16, an updated 
position statement from the International Society for Prenatal Diagnosis (ISPD)17, and a 
guideline from the National Society of Genetic Counselors (NSGC)18. These guidelines 
cover a range of issues from the clinical application of cfDNA screening to appropriate 
counseling surrounding the test and associated ethical issues.
All but three policies mention at least one of these updated guidelines in their summaries of 
the evidence reviewed in making their coverage determinations. The most commonly cited 
source was the committee opinion from ACOG and SMFM, but policies typically mentioned 
several different sources (Table 3).
Timeline for coverage decisions
Temporal trends in coverage for high and average risk women are outlined in Figure 1, 
showing illustrative payer coverage decisions in relationship to either professional guideline 
changes or publication of key clinical studies. The first positive coverage decisions among 
these 19 payers was noted in December 2012, temporally following a 2012 recommendation 
by the ACOG stating that cfDNA screening be offered to women at increased risk of fetal 
aneuploidy. Policy revision histories are incompletely available, but by mid-2013, at least 
nine of the 19 payers had specific policies addressing cfDNA prenatal screening with 
affirmative coverage in high risk singleton pregnancies (data not shown).
Dervan et al. Page 6
Genet Med. Author manuscript; available in PMC 2017 May 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
As noted in payer policies, over the next two years, large clinical validity studies involving 
thousands of women were published assessing the performance of cfDNA screening in 
routine screening of high risk women.13,19–22 Studies were completed using the technology 
platforms for all four major manufacturers. Subsequently, several large clinical validity 
studies were undertaken in average risk women.23–25 By mid-2015, following the 
publication of two large, well-designed, prospective studies in average risk women on two 
different platforms, the first major prenatal organization, the International Society of 
Prenatal Diagnosis, released updated guidelines supporting the clinical use of cfDNA 
screening in screening for trisomy 21 for all risk categories. Later in 2015, two other groups 
(ACOG and SMFM) released a combined, updated committee opinion reversing their stance 
that cfDNA screening is inappropriate for average risk women, stating that any patient, 
regardless of her risk status, may choose cell-free DNA analysis as a screening strategy for 
common aneuploidies when counseled appropriately on the risks, benefits, and alternatives, 
though conventional screening methods are still recommended as a first-line given current 
evidence.26 Coincident with the most recent revision to the ACOG/SMFM opinion, one plan 
made the decision to expand coverage to average risk pregnancies (Figure 1), citing this 
updated guideline, followed by 7 more plans within the next 4 months (data not shown).
DISCUSSION
When we systematically evaluated coverage policies for cfDNA screening among the largest 
19 private payers with publically available policies, we found that regardless of the specific 
sequencing platform or test output, the vast majority of payers applied the conventional 
evaluation framework of analytical validity, clinical validity and clinical utility when 
assessing evidence for coverage determinations. In particular, the published evidence base 
supporting the clinical validity of the test in high risk women and professional guideline 
support for testing were the most common reasons for positive coverage decisions. 
Technology assessments that included modeled evidence of the clinical utility of testing for 
trisomies 21, 18 and 13 in high risk women were also important factors in justifying 
coverage.
Payers had varying interpretations of the adequacy of the clinical validity and clinical utility 
of cfDNA screening in average risk women (affirmative coverage in eight of 19 policies), 
despite policies citing similar types of evidence (Table 3). Whenever described, payers had a 
consistent definition of clinical utility as a “change in net health outcomes,” so the definition 
was not an obvious source of difference. The only evidence regarding health outcomes 
associated with cfDNA screening in either high risk or average risk pregnancies was 
developed from decision analytic models, suggesting that in certain circumstances, a well-
conducted model can influence payer decision-making.27 Whether decision analytic models 
are sufficient evidence of clinical utility in other complex genetic tests is undetermined.27,28
One consistent evidence gap highlighted in coverage policies was the lack of robust 
analytical validity data, which is not unexpected given that all cfDNA screening tests are 
laboratory developed tests (LDTs) and public reporting of technical performance data is not 
required by Clinical Laboratory Improvement Amendments (CLIA), which are federally 
regulated standards that govern LDTs. Some payers stated that acceptable analytic validity is 
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generally assumed for cfDNA screening based on laboratories meeting quality standards 
under CLIA. Although many payers acknowledged this evidence gap, it was not ultimately a 
barrier to coverage. Test performance and reliability is a central issue in the current debate 
about the FDA’s initiative to regulate LDTs such as cfDNA screening tests.29 While the 
payers in our analysis do not seem to differentiate among the various test technology 
platforms or interpretation algorithms currently, future increased regulation and analytical 
and clinical validity data requirements may lead to differential coverage decisions for 
specific cfDNA screening methods and platforms based on FDA clearance. This issue seems 
particularly relevant in the case of screening for trisomies 13 and 18, where the test failure 
rate may be higher due to low levels of placental cfDNA than in euploid pregnancies.30 
Moreover, likely future expansion of cfDNA screening to detect additional genetic 
conditions will only exacerbate this lack of transparency with respect to analytic validity.
With one exception, payers in our study did not cover cfDNA screening for sex chromosome 
aneuploidies, and no policies covered cfDNA screening for microdeletions, though almost 
all test manufacturers offer cfDNA screening for these conditions (Table 4) despite 
consensus between the payer community and professional societies about the lack of 
compelling evidence of clinical validity. Thus, they are being promoted without an 
understanding of the benefits and harms of their use in clinical practice.3,31 While the 
coverage determinations are clear, cfDNA screening for these additional conditions may still 
be reimbursed given the lack of granularity in billing (Current Procedural Terminology or 
CPT) codes used to identify the comprehensiveness of the test performed. As cfDNA 
screening expands to assess for an increasing number of genetic conditions and competition 
in test development heightens, this discrepancy will become only more prominent.
What is also apparent is that the largest private payers have responded rapidly to the 
evolving evidence base for cfDNA screening, issuing new coverage policies within very 
short time periods of new peer-reviewed publications or major professional guideline 
updates (Figure 1). The 2015 ACOG/SMFM committee opinion was released a few months 
prior to the first observed change in payer coverage policies for average risk women, 
suggesting that payers closely follow professional guideline recommendations. However, 
half of all policies updated since the release of that committee opinion continued to view the 
overall evidence for cfDNA screening in average risk pregnancies for trisomy 21 as 
insufficient (Table 3). As has been observed previously, there is variation in payer coverage 
decision-making even when the same evidence base is available.32 One explanation may be 
that the updated clinical guideline did not recommend cfDNA screening as a first line 
screening tool, but rather removed a prior recommendation against its use in average risk 
women with singleton pregnancies, a stance that was reiterated in a December 2015 
confirmatory guidance statement.33
In addition, although all professional guidelines emphasize the importance of pre-test and 
post-test counseling, only twelve payers referenced the need for genetic counseling in their 
coverage policies (with only five highlighting the clear need for patient guidance on 
potential false positives), and no coverage policies mandated counseling as a requirement for 
obtaining coverage. It has been shown for other commonly used genetic tests that counseling 
falls markedly short of what is recommended by professional societies34 due in part to cost 
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and feasibility. This is exacerbated by a shortage of genetic counselors18 and clinical 
geneticists.35 The potential for misinterpretation of test results is a major concern with the 
coverage expansion of cfDNA screening to average risk pregnancies. These tests are not 
diagnostic tests, and false positives have been reported in the literature associated with 
placental mosaicism, maternal mosaicism, and vanishing twin.36–38 In addition, some 
patients fail to get an interpretable result due to inadequate circulating fetal DNA 
(particularly in obese women), failed sequencing, or other problems with the test, and the 
impact of cfDNA screening on this population is unclear and not addressed in cited models.
Limitations
Our study had several limitations, including that we only analyzed coverage policies from 
private insurers. As Medicaid covers almost half of births in the US,39 future analyses 
looking at Medicaid coverage will be informative. In addition, we were limited by the level 
of detail provided in the coverage policies by each payer and the policies were highly 
variable in their detail and clarity. Our conclusions may not reflect the actual evidence 
review processes undertaken by individual payers. Finally, all of the payers that expanded 
cfDNA screening coverage to average risk pregnancies were Blue Cross Blue Shield plans, 
though not all of the Blue Cross Blue Shield plans analyzed covered average risk. While 
each plan makes independent coverage decisions, their actions may be interdependent in 
ways that are unknown to us as researchers.
Conclusion
Our analysis revealed that cfDNA screening has received broad and rapid private payer 
coverage in certain indications, unlike other new sequencing-based tests that have faced 
reimbursement challenges. There are general concerns about the breadth and complexity of 
massively parallel sequencing-based tests being a barrier to informed coverage decision-
making. These concerns were overcome in cfDNA screening by widespread availability of 
adequate clinical validity and clinical utility evidence in high risk pregnancies. Given 
expansion of cfDNA screening to other genetic conditions and even the entire fetal 
genome,40 our analysis of the evidentiary framework used in payer decision-making may 
serve as an indicator for test developers and researchers regarding likely hurdles to be 
confronted in payer coverage decisions going forward. One caveat, however, is that the first 
cfDNA screening indications receiving positive coverage decisions were syndromes like 
Down syndrome for which there is extensive knowledge about the natural history and 
management of the condition. As cfDNA screening expands into screening for more 
clinically heterogeneous genetic conditions, where fewer data are available regarding 
medical implications and management, the appropriate clinical follow up after a positive test 
is less clear and the likelihood that modeling studies of clinical utility will suffice for 
decision-making is undetermined. Moreover, payers continue to evaluate each chromosomal 
abnormality as a separate test without any evidence of viewing cfDNA screening as a 
“panel” that has advantages because it can screen for multiple conditions simultaneously. In 
addition, as use of cfDNA screening continues to grow, appropriate genetic counseling 
services have been identified as a foreseeable bottleneck, particularly concerning issues of 
informed decision-making when cfDNA screening is used in low risk populations for a 
particular condition where even highly specific tests will have high proportions of false 
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positives. Positive coverage of cfDNA screening has enabled expansion of cfDNA screening 
tests into routine care, but much remains to be learned now about the implementation and 
outcomes of expanded use of these complex sequencing tests in practice.
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Figure 1. Temporal trends in coverage of cell-free DNA prenatal genetic screening tests in women 
of high and average risk for fetal aneuploidy with professional guideline changes, technology 
assessments and representative clinical publications
Five-year timeline of initial cfDNA screening test launch and illustrative payer coverage 
decisions (all above timeline) with corresponding professional society guideline changes, 
technology assessment reports and key clinical publications with author, journal and cfDNA 
screening platform noted (all below timeline); all events with dates of publication (month/
year).
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